高リスク消化管間質腫瘍 に対するGleevecは長い方が良い
2011年 06月 06日
American Society of Clinical Oncology (ASCO) meeting関連報告
http://www.medpagetoday.com/MeetingCoverage/ASCO/26862
高リスク消化管間質腫瘍 gastrointestinal stromal tumors (GIST) に対するExtending adjuvant imatinib (Gleevec) 治療は、12ヶ月より36ヶ月が生存改善
術後治療比較で、92％ ｖ 81.7％ P=0.019
"Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)"
J Clin Oncol 29: 2011 (suppl; abstr LBA1).
http://www.medpagetoday.com/MeetingCoverage/ASCO/26862
高リスク消化管間質腫瘍 gastrointestinal stromal tumors (GIST) に対するExtending adjuvant imatinib (Gleevec) 治療は、12ヶ月より36ヶ月が生存改善
術後治療比較で、92％ ｖ 81.7％ P=0.019
"Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)"
J Clin Oncol 29: 2011 (suppl; abstr LBA1).
by internalmedicine | 2011-06-06 08:44 | がん
